IMP321: Ph I TACTI-mel ongoing

An independent DSMB recommended continuation of the open-label, Australian Phase I TACTI-mel trial evaluating subcutaneous IMP321 every 2 weeks plus Keytruda pembrolizumab. The company will now begin ...